EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Unveiling Risk Factors for Treatment Failure in Patients with Graves’ Disease: A Nationwide Cohort Study in Korea

Jung A Kim, Kyeong Jin Kim, Jimi Choi, Kyoung Jin Kim, Eyun Song, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik und 1 weitere

Endocrinology and Metabolism · 2025

DOI: 10.3803/enm.2024.2093 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Endocrinology and Metabolism, 2025. Verfasst von Jung A Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Graves Disease, Thyroidectomy, Antithyroid Agents, Iodine Radioisotopes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antithyroid drug (ATD) treatment is the preferred initial treatment for Graves’ disease (GD) in South Korea, despite higher treatment failure rates than radioactive iodine (RAI) therapy or thyroidectomy. This study aimed to evaluate the incidence of treatment failure associated with the primary modalities for GD treatment in real-world practice.

Methods

We included 452,001 patients diagnosed with GD between 2004 and 2020 from the Korean National Health Insurance Service-National Health Information Database. Treatment failure was defined as switching from ATD, RAI, or thyroidectomy treatments, and for ATD specifically, inability to discontinue medication for over 2 years.

Results

Mean age was 46.2 years, with females constituting 70.8%. Initial treatments for GD included ATDs (98.0%), thyroidectomy (1.3%), and RAI (0.7%), with a noted increment in ATD application from 96.2% in 2004 to 98.8% in 2020. During a median follow- up of 8.5 years, the treatment failure rates were 58.5% for ATDs, 21.3% for RAI, and 2.1% for thyroidectomy. Multivariate analysis indicated that the hazard ratio for treatment failure with ATD was 2.81 times higher than RAI. RAI treatments ≥10 mCi had 37% lower failure rates than doses

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves DiseaseThyroidectomyAntithyroid AgentsIodine RadioisotopesHumansFemaleRepublic of KoreaMiddle AgedMaleTreatment FailureAdultRisk FactorsCohort StudiesFollow-Up StudiesAgedRetrospective StudiesPrognosisYoung Adult

Stichwörter der Autor:innen

Graves diseaseRisk factorsTreatment failure

Substanzen

Antithyroid AgentsIodine Radioisotopes

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

Förderung

  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare

Zitieren

APA

Kim, J. A., Kim, K. J., Choi, J., Kim, K. J., Song, E., Yu, J. H., Kim, N. H., Yoo, H. J., Seo, J. A., Kim, N. H., Choi, K. M., Baik, S. H., & Kim, S. G. (2025). Unveiling Risk Factors for Treatment Failure in Patients with Graves’ Disease: A Nationwide Cohort Study in Korea. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2024.2093

Vancouver

Kim JA, Kim KJ, Choi J, Kim KJ, Song E, Yu JH, et al. Unveiling Risk Factors for Treatment Failure in Patients with Graves’ Disease: A Nationwide Cohort Study in Korea. Endocrinology and Metabolism. 2025. doi:10.3803/enm.2024.2093

BibTeX
@article{Kim2025,
  author = {Kim, Jung A and Kim, Kyeong Jin and Choi, Jimi and Kim, Kyoung Jin and Song, Eyun and Yu, Ji Hee and Kim, Nam Hoon and Yoo, Hye Jin and Seo, Ji A and Kim, Nan Hee and Choi, Kyung Mook and Baik, Sei Hyun and Kim, Sin Gon},
  title = {Unveiling Risk Factors for Treatment Failure in Patients with Graves’ Disease: A Nationwide Cohort Study in Korea},
  journal = {Endocrinology and Metabolism},
  year = {2025},
  doi = {10.3803/enm.2024.2093}
}
Kostenlos starten →